New York, NY—October 7, 2004
Merck's voluntary withdrawal of Vioxx® is causing concern among patients afflicted by a variety of orthopedic and rheumatic conditions. Whether patients are recovering from joint replacement surgery or sports injuries, or suffering from arthritis, osteoarthritis or lupus, they are looking to their healthcare practitioners for advice on alternative medications that will them relieve their pain.
The following Hospital for Special Surgery's doctors are available to comment on the Vioxx® withdrawal and its implications for patients:
Theodore R. Fields, MD, FACP
Associate Attending Physician
Available to discuss: Medication alternatives to Vioxx®, reasons for withdrawal of Vioxx, non-medication approaches to arthritis, the COX-2 selective vs non-selective anti-inflammatory agents.
Joseph A. Markenson, MD
Available to discuss: Current drug studies involving patients with rheumatic disease (rheumatoid arthritis, osteoarthritis, and lupus), medication alternatives to Vioxx®, reasons for withdrawal of Vioxx®, non-medication approaches to arthritis, the COX-2 selective vs non-selective anti-inflammatory agents.
Thomas J.A. Lehman, MD
Chief, Division of Pediatric Rheumatology
Available to discuss: Implications for children with Juvenile Rheumatoid Arthritis
Lehman, author of author of It's Not Just Growing Pains, published by Oxford University Press, devotes a section of the book to the various medications available to children with rheumatic diseases and the reasons for taking medications even if they pose potential risks to children.
Scott A. Rodeo, MD
Clinician-scientist, Department of Orthopedic Surgery (Sports Medicine and Shoulder Service) and the Research Department (Laboratory for Soft Tissue Research) and Associate team physician for New York Giants
Available to discuss: Implications for athletes and sports injuries
Michael D Lockshin, MD
Director, Barbara Volcker Center for Women and Rheumatic Disease
Available to discuss: Alternatives for patients suffering from rheumatic diseases
For more information on the Vioxx® voluntary withdrawal, please visit:
Special Report: Merck withdraws Vioxx from the Market
Reflections on the withdrawal of Vioxx from the market
For a discussion of how to reduce the side effects of COX-2 inhibitors – the group of drugs in which Vioxx® belongs – please visit:
Guidelines to Help Reduce the Side-Effects of COX-2 Selective Drugs (Types of non-steroidal anti-inflammatory agents)
For information on the Vioxx® withdrawal and its implications for the management of osteoarthritis for patients, please visit:
An In-Depth Overview of Osteoarthritis
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.